Buchang Pharmaceutical: Yangzheng Heji obtains Malaysia drug registration certificate

2026-04-10 02:56:04

People’s Financial News, April 8 — Boshang Pharmaceutical (603858) announced on April 8 that recently, the company received the drug registration certificate issued by the Malaysian Drug Control Authority. The company’s wholly-owned subsidiary, Yangling Boshang Pharmaceutical Co., Ltd., product Yangzheng Heji, meets the Malaysian traditional Chinese medicine registration standards. Yangzheng Heji is an exclusive product of the company and has entered the “National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug List” (2025 Edition). Its main functions and indications are: to tonify qi and strengthen the spleen, nourish the liver and kidneys. It is used for qi and yin deficiency caused by chemotherapy in tumor patients, with symptoms such as fatigue, weakness, shortness of breath, reluctance to speak, five-center heat, dry mouth and throat, and leukopenia.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes